Zolpidem Tartrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318998

CAS#: 99294-93-6 (Tartrate)

Description: Zolpidem is a prescription medication used for the treatment of insomnia and some brain disorders. This drug is a controlled substance and has been discontinued.

Price and Availability


Ask price

Ask price

Ask price

Zolpidem Tartrate is a controlled substance, and has been discontinued.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318998
Name: Zolpidem Tartrate
CAS#: 99294-93-6 (Tartrate)
Chemical Formula: C42H48N6O8
Exact Mass:
Molecular Weight: 764.88
Elemental Analysis: C, 65.95; H, 6.33; N, 10.99; O, 16.73

Related CAS #: 99294-93-6 (Tartrate); 82626-48-0 (free base)  

Synonym: SL 80.0750; SL-800750-23-N; Zolpidem Tartrate. brand names Ambien, Ambien CR, Intermezzo, Stilnox, Stilnoct, Sublinox, Hypnogen, Lunata, Zonadin, Sanval, Zolsana and Zolfresh

IUPAC/Chemical Name: N,N-dimethyl-2-(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)acetamide;((2R,3R)-2,3-dihydroxysuccinate) (2:1)


InChi Code: InChI=1S/2C19H21N3O.C4H6O6/c2*1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19;5-1(3(7)8)2(6)4(9)10/h2*5-10,12H,11H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1

SMILES Code: O=C(N(C)C)CC1=C(C2=CC=C(C)C=C2)N=C3C=CC(C)=CN31.O=C(N(C)C)CC4=C(C5=CC=C(C)C=C5)N=C6C=CC(C)=CN64.O=C(O)[C@H](O)[C@@H](O)C(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Related CAS#
99294-93-6 (Tartrate); 82626-48-0 (free base)


1: Martinez-Ramirez D, Paz-Gomez V, Rodriguez RL. Response to zolpidem in oromandibular dystonia: a case report. Parkinsonism Relat Disord. 2015 Feb;21(2):154-5. doi: 10.1016/j.parkreldis.2014.11.006. Epub 2014 Nov 20. Review. PubMed PMID: 25443554.

2: Stranks EK, Crowe SF. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol. 2014;36(7):691-700. doi: 10.1080/13803395.2014.928268. Epub 2014 Jun 16. Review. PubMed PMID: 24931450.

3: Pergolizzi JV Jr, Taylor R Jr, Raffa RB, Nalamachu S, Chopra M. Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness. Sleep Disord. 2014;2014:527109. doi: 10.1155/2014/527109. Epub 2014 Feb 5. Review. PubMed PMID: 24649369; PubMed Central PMCID: PMC3932650.

4: Fitzgerald AC, Wright BT, Heldt SA. The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors. Psychopharmacology (Berl). 2014 May;231(9):1865-96. doi: 10.1007/s00213-014-3457-x. Epub 2014 Feb 22. Review. PubMed PMID: 24563183.

5: Victorri-Vigneau C, Gérardin M, Rousselet M, Guerlais M, Grall-Bronnec M, Jolliet P. An update on zolpidem abuse and dependence. J Addict Dis. 2014;33(1):15-23. doi: 10.1080/10550887.2014.882725. Review. PubMed PMID: 24467433.

6: Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. 2014;20(26):4167-84. Review. PubMed PMID: 24025057.

7: Yang LP, Deeks ED. Sublingual zolpidem (Edluar™; Sublinox™). CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y. Review. PubMed PMID: 23034583.

8: Low-dose sublingual zolpidem (Intermezzo) for insomnia due to middle-of-the-night awakening. Med Lett Drugs Ther. 2012 Apr 2;54(1387):25-6. Review. PubMed PMID: 22469649.

9: Foda NH, Ali SM. Zolpidem tartrate. Profiles Drug Subst Excip Relat Methodol. 2012;37:413-38. doi: 10.1016/B978-0-12-397220-0.00011-8. Epub 2012 Mar 19. Review. PubMed PMID: 22469325.

10: Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother. 2012 Apr;13(6):879-93. doi: 10.1517/14656566.2012.667074. Epub 2012 Mar 19. Review. PubMed PMID: 22424586.

11: Zolpidem oral spray (zolpimist) for insomnia. Med Lett Drugs Ther. 2012 Feb 20;54(1384):14-5. Review. PubMed PMID: 22354280.

12: Staner L, Danjou P, Luthringer R. A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia. Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197. Review. PubMed PMID: 22288669.

13: Daley C, McNiel DE, Binder RL. "I did what?" Zolpidem and the courts. J Am Acad Psychiatry Law. 2011;39(4):535-42. Review. PubMed PMID: 22159981.

14: Dang A, Garg A, Rataboli PV. Role of zolpidem in the management of insomnia. CNS Neurosci Ther. 2011 Oct;17(5):387-97. doi: 10.1111/j.1755-5949.2010.00158.x. Epub 2010 Jun 11. Review. PubMed PMID: 20553305.

15: Kovacic P, Somanathan R. Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation. Oxid Med Cell Longev. 2009 Jan-Mar;2(1):52-7. Review. PubMed PMID: 20046645; PubMed Central PMCID: PMC2763231.

16: Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009 Aug 15;5(4):377-83. Review. PubMed PMID: 19968019; PubMed Central PMCID: PMC2725260.

17: Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009 Oct 15;5(5):471-6. Review. PubMed PMID: 19961034; PubMed Central PMCID: PMC2762721.

18: Myslobodsky M. The paradox of caffeine-zolpidem interaction: a network analysis. Curr Drug Targets. 2009 Oct;10(10):1009-20. Review. PubMed PMID: 19860644.

19: Owen RT. Novel zolpidem formulations. Drugs Today (Barc). 2009 May;45(5):395-400. doi: 10.1358/dot.2009.45.5.1370457. Review. PubMed PMID: 19584967.

20: Bogan RK. Treatment options for insomnia--pharmacodynamics of zolpidem extended-release to benefit next-day performance. Postgrad Med. 2008 Sep;120(3):161-71. doi: 10.3810/pgm.2008.09.1916. Review. PubMed PMID: 18824834.